PFE Tender Offer for Icagen Succeeds - Analyst Blog
September 08 2011 - 10:47AM
Zacks
Pfizer Inc. (PFE) recently announced the
successful completion of the initial cash tender offer for all
outstanding shares of Icagen, Inc. (ICGN). The
tender offer period expired on September 2, 2011.
As of September 2, 2011, about 4,617,045 shares of Icagen’s
common stock were validly tendered. Besides this, Pfizer owns
1,067,015 shares of Icagen’s common stock. Taken together, this
represents 54% of the fully-diluted shares of Icagen. This
indicates the fulfillment of the condition for the minimum number
of shares that need to be tendered so as to allow Pfizer to accept
for payment and pay for such shares.
In addition to announcing the successful completion of the
initial cash tender offer, Pfizer announced the commencement of a
subsequent offering period that is scheduled to expire on September
12, 2011 (6:00 p.m., New York City time).
Pfizer had first announced its intention to acquire Icagen in
July 2011 for $6 per share. The total value of the deal, including
the value of the shares already owned by Pfizer, is about $56
million.
Earlier in August 2007, Pfizer and Icagen had entered into a
collaboration for the discovery, development and commercialization
of compounds that modify three specific sodium ion channels that
are to be used as potential treatments for pain and related
disorders. With the help of these sodium channels, the companies
are seeking to develop effective treatments for serious pain
disorders, which will have fewer side effects.
With the Icagen deal, Pfizer is looking to add to its already
diversified product portfolio. Icagen currently has two programs in
epilepsy and pain.
Neutral on Pfizer
We currently have a Neutral recommendation on Pfizer, which
carries a Zacks #3 Rank (short-term Hold rating). While near-term
earnings growth will come in the form of cost cutting and share
repurchases, longer-term growth will be dependent on the success of
drug development.
ICAGEN INC (ICGN): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
Zacks Investment Research
Icagen, Inc. (MM) (NASDAQ:ICGN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Icagen, Inc. (MM) (NASDAQ:ICGN)
Historical Stock Chart
From Dec 2023 to Dec 2024